Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.49 |
| ▸ | WNT3A | P56704 | 3/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13470208 | 0.80 | ALDH1A1 (0.49) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL29355245 | 0.78 | CES2 (0.64) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL2470002 | 0.78 | CTNNB1 (0.71) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL253276 | 0.78 | CES2 (0.64) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL1983225 | 0.77 | L3MBTL1 (0.54) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL2639445 | 0.76 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL422631 | 0.76 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL422632 | 0.76 | CES2 (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL4134594 | 0.75 | KMT2A (0.59) | CES2CES1ALDH1A1KMT2ASMN1; SMN2 | |
| 2-Picolinic Acid SCHEMBL10362935 | 0.75 | LMNA (0.83) | CES2CES1L3MBTL1LMNANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225618-A1 | IDO Inhibitors | MAUTINO MARIO (US) | 2019-07-25 | — | — | US | disclosed |
| US-10233190-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3348558-A1 | COMPOSITIONS COMPRISING FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180118753-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9850248-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160362412-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2016-12-15 | — | — | US | disclosed |
| US-9388191-B2 | Fused imidazole derivatives useful as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| EP-3018132-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9260434-B2 | Fused imidazole derivatives useful as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2697227-B1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-02-03 | — | — | EP | disclosed |
| US-20160002249-A1 | Fused Imidazole Derivatives Useful as IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2016-01-07 | — | — | US | disclosed |
| US-20140066625-A1 | Fused Imidazole Derivatives Useful as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362412-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CES2 3022/4885CES1 986/4885L3MBTL1 2800/4885 |
| US-20180118753-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CES2 3022/4885CES1 986/4885L3MBTL1 2800/4885 |
| US-20190225618-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CES2 3047/4885CES1 958/4885L3MBTL1 2743/4885 |
| US-10233190-B2 | IDO inhibitors | IDO1, IDO2, INMT | CES2 3022/4885CES1 986/4885L3MBTL1 2800/4885 |
| US-20140066625-A1 | Fused Imidazole Derivatives Useful as IDO Inhibitors | IDO1, IDO2, INMT | CES2 2842/4885CES1 1818/4885L3MBTL1 2197/4885 |
| US-20160002249-A1 | Fused Imidazole Derivatives Useful as IDO Inhibitors | IDO1, IDO2, INMT | CES2 3213/4885CES1 1606/4885L3MBTL1 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.